secwatch / observer
8-K filed May 7, 2026, 7:59 PM ET ticker INSM CIK 0001104506
earnings confidence high sentiment positive materiality 0.85

Insmed Q1 revenue $306M, BRINSUPRI $207.9M (44% QoQ); reiterates FY guidance

INSMED Inc

2026-Q1 EPS reported -$0.76 revenue$305,964,000
item 2.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001140361-26-019430
form_type
8-K
ticker
INSM
cik
0001104506
company_name
INSMED Inc
filed_at
2026-05-07T23:59:59+00:00
discovered_at
2026-05-14T18:02:31.959368+00:00
generated_at
2026-05-14T21:23:57.363225+00:00
sec_items
["2.02", "9.01"]
event_type
earnings
sentiment
positive
materiality_score
0.85
calibrated_materiality_score
0.85
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001140361-26-019430
json_url
https://secwatch.observer/filing/0001140361-26-019430.json
markdown_url
https://secwatch.observer/filing/0001140361-26-019430.md
text_url
https://secwatch.observer/filing/0001140361-26-019430.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/0001140361-26-019430-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/ef20072589_8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

f1403e15a3ea5178af3878b60ed383372081dfb6

INSMED Inc reported the first quarter ended March 31, 2026 results: revenue $306.0 Million. Guidance reaffirmed.

99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

Comparable filings

GMRS

GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B

GMR Solutions Inc. June 1, 2026, 4:45 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —

Comparable filing

today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted

Filing page SEC filing

HPE

HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework

Hewlett Packard Enterprise Co June 1, 2026, 4:09 PM ET earnings Items 1.01, 2.02, 5.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —

Comparable filing

gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,

Filing page SEC filing

CRDO

Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs

Credo Technology Group Holding Ltd June 1, 2026, 4:08 PM ET earnings Items 2.02, 5.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —

Comparable filing

On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.

Filing page SEC filing

URG

Ur-Energy Q1 2026: pounds captured up 41% QoQ, avg price $70.98, Shirley Basin commenced

UR-ENERGY INC May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —

Comparable filing

a 14% increase over Q4 2025 and a 13% increase over Q1 2025. Financial Performance ◾ Contracted Sales: We sold 55,000 produced pounds of U 3 O 8 as anticipated, generating $3.9 million in revenue, with a majority of our 2026 deliveries scheduled for the latter part of the year to complement the ramp-up and start-up schedules of Lost Creek and Shirley Basin. ◾

Filing page SEC filing

ACH

Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization

ACCENDRA HEALTH INC/VA/ May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —

Comparable filing

Commission this morning. ​ Details on First Quarter 2026 Results ​ ​ First Quarter Results (1) ​ ($ in millions, except per share data) ​ ​ ​ 1Q26 ​ ​ ​ 1Q25 Net Revenue ​ $ 627.8 ​ $ 673.9 ​ ​ ​ ​ ​ ​ ​ Loss from continuing operations, net of tax, GAAP ​ $ (6.5) ​ $ (3.8) Adj. net (loss) income from continuing operations, Non-GAAP ​ $ (3.1) ​ $ 23.2 ​ ​ ​

Filing page SEC filing

LQDA

Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M

Liquidia Corp May 11, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —

Comparable filing

First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.

Filing page SEC filing

TH

Target Hospitality Q1 revenue up 4% but net loss widens to $13M; announces $750M AI infrastructure contract

Target Hospitality Corp. May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —

Comparable filing

today reported results for the three months ended March 31, 2026. ​ Financial Highlights for the quarter ended March 31, 2026 ​ ● Revenue of $72.8 million. ● Net loss of ($13.0) million. ● Basic and diluted loss per share of $0.13 . ● Adjusted EBITDA (1) of $9.9 million. ● Net Cash Provided by Operating Activities of $7.0 million and Discretionary Cash

Filing page SEC filing

FSK

FSK posts Q1 GAAP loss of $1.57/sh, NAV falls to $18.83; announces $150M preferred, tender, buyback

FS KKR Capital Corp May 11, 2026, 7:59 PM ET earnings Items 1.01, 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —

Comparable filing

Earnings (Loss) per share of ($1.57), compared to Earnings (Loss) per share of ($0.41) for the quarter ended December 31, 2025

Filing page SEC filing

Source: SEC EDGAR
accession 0001140361-26-019430
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.